TrialCNS drugs2026

Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized Trial.

Matin Mortazavi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.